Literature DB >> 1321006

Calculation of received dose intensity for combinations of drugs using small-cell lung carcinoma treatment regimens as examples.

G L Wampler1, J G Fryer.   

Abstract

Programs are presented for the calculation of received dose intensity in combination chemotherapy regimens. These provide methods for determining the final dose intensity, the mean cumulative dose intensity together with its standard error, and other tabular and graphic summaries. Two ways of dividing patients into high and low received-dose-intensity groups are proposed. Methods are illustrated using data from Mid-Atlantic Oncology Program (MAOP) 2183, a phase III evaluation of a six-drug alternating combination vs a three-drug "standard" combination treatment for extensive small-cell lung cancer. Comparisons of received dose intensity with demographic and outcome variables are presented.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1321006     DOI: 10.1007/bf00686312

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  24 in total

1.  Dose intensity in the treatment of diffuse large-cell lymphoma.

Authors:  J R Anderson; M T Santarelli; B Peterson
Journal:  J Clin Oncol       Date:  1990-11       Impact factor: 44.544

2.  A formula to estimate the approximate surface area if height and weight be known. 1916.

Authors:  D Du Bois; E F Du Bois
Journal:  Nutrition       Date:  1989 Sep-Oct       Impact factor: 4.008

3.  Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol.

Authors:  C R Nichols; S D Williams; P J Loehrer; F A Greco; E D Crawford; J Weetlaufer; M E Miller; A Bartolucci; L Schacter; L H Einhorn
Journal:  J Clin Oncol       Date:  1991-07       Impact factor: 44.544

4.  Intensive weekly chemotherapy for good-prognosis patients with small-cell lung cancer.

Authors:  D W Miles; H M Earl; R L Souhami; P G Harper; R Rudd; C M Ash; L James; C W Trask; J S Tobias; S G Spiro
Journal:  J Clin Oncol       Date:  1991-02       Impact factor: 44.544

5.  The description of chemotherapy delivery: options and pitfalls.

Authors:  C M Coppin
Journal:  Semin Oncol       Date:  1987-12       Impact factor: 4.929

Review 6.  The importance of dose intensity in chemotherapy of metastatic breast cancer.

Authors:  W Hryniuk; H Bush
Journal:  J Clin Oncol       Date:  1984-11       Impact factor: 44.544

Review 7.  Dose-response in the treatment of breast cancer: a critical review.

Authors:  I C Henderson; D F Hayes; R Gelman
Journal:  J Clin Oncol       Date:  1988-09       Impact factor: 44.544

8.  Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation.

Authors:  C R Nichols; G Tricot; S D Williams; K van Besien; P J Loehrer; B J Roth; L Akard; R Hoffman; R Goulet; S N Wolff
Journal:  J Clin Oncol       Date:  1989-07       Impact factor: 44.544

9.  Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung.

Authors:  R J Klasa; N Murray; A J Coldman
Journal:  J Clin Oncol       Date:  1991-03       Impact factor: 44.544

10.  The effect of intensity of administered treatment on the outcome of germ cell tumours treated with POMB/ACE chemotherapy.

Authors:  S M Crawford; E S Newlands; R H Begent; G J Rustin; K D Bagshawe
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

View more
  2 in total

1.  Neutropenia and relative dose intensity on adjuvant FOLFOX chemotherapy are not associated with survival for resected colon cancer.

Authors:  Martin Smoragiewicz; Khodadad R Javaheri; Yaling Yin; Sharlene Gill
Journal:  J Gastrointest Cancer       Date:  2014-12

2.  Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.

Authors:  Beatrice Seddon; Sandra J Strauss; Jeremy Whelan; Michael Leahy; Penella J Woll; Fiona Cowie; Christian Rothermundt; Zoe Wood; Charlotte Benson; Nasim Ali; Maria Marples; Gareth J Veal; David Jamieson; Katja Küver; Roberto Tirabosco; Sharon Forsyth; Stephen Nash; Hakim-Moulay Dehbi; Sandy Beare
Journal:  Lancet Oncol       Date:  2017-09-04       Impact factor: 41.316

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.